BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Calico Life Sciences LLC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Calico Life Sciences LLC's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05757141-7528@assetmemo.bio
DTSTAMP:20261121T010116Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fosigotifator: Phase 1/2 readout est. (NCT05757141)
DESCRIPTION:Fosigotifator\, phase 1/2.\nStudy: An Open-Label Exploratory St
 udy of Fosigotifator in Participants With Vanishing White Matter Disease\n
 Estimated primary completion: November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05757141
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
